Indivior PLC (INDV)

NMS – Цена в реальном времени. Валюта: USD

41.83

+0.54 (1.31%)

При закрытии: Jun 26, 2026, 4:00 PM EDT

41.96

+0.13 (0.31%)

После закрытия: Jun 26, 2026, 7:59 PM EDT

Обзор
Новости
График
Финансы
Дивиденды
Прогноз
Владельцы
Профиль

Indivior PLC (INDV)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Indivior PLC (INDV)

INDV and the Shift to Long-Acting Opioid Use Disorder Care in 2026

Is Indivior Stock a Buy After Higher 2026 Guidance?

INDV Stock: What Sublocade Growth Signals for 2026

Recent Price Trend in Indivior Pharmaceuticals Inc. (INDV) is Your Friend, Here's Why

Indivior: A Stronger Business Than When I First Covered It

5 Top-Ranked Efficient Stocks Beating Industry Peers on Key Metrics

Does Indivior Pharmaceuticals Inc. (INDV) Have the Potential to Rally 32.48% as Wall Street Analysts Expect?

Видео

No Data

Пресс-релизы

New Studies Show Adherence to Monthly Injectable Buprenorphine is Associated with Relapse Reduction and Lower Healthcare Utilization

Indivior Announces $175 Million Accelerated Share Repurchase

Indivior Reports First Quarter 2026 Financial Results and Raises Full-Year 2026 Guidance

Indivior Presents New Real-World Data at ASAM 2026 Annual Conference, Supporting Remission as a Treatment Outcome and Reinforcing the Clinical Benefits of Monthly Injectable Buprenorphine for Opioid Use Disorder

Search stocks

Indivior PLC (INDV)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Indivior PLC (INDV)

INDV and the Shift to Long-Acting Opioid Use Disorder Care in 2026

Is Indivior Stock a Buy After Higher 2026 Guidance?

INDV Stock: What Sublocade Growth Signals for 2026

Recent Price Trend in Indivior Pharmaceuticals Inc. (INDV) is Your Friend, Here's Why

Indivior: A Stronger Business Than When I First Covered It

5 Top-Ranked Efficient Stocks Beating Industry Peers on Key Metrics

Does Indivior Pharmaceuticals Inc. (INDV) Have the Potential to Rally 32.48% as Wall Street Analysts Expect?

Видео

No Data

Пресс-релизы

New Studies Show Adherence to Monthly Injectable Buprenorphine is Associated with Relapse Reduction and Lower Healthcare Utilization

Indivior Announces $175 Million Accelerated Share Repurchase

Indivior Reports First Quarter 2026 Financial Results and Raises Full-Year 2026 Guidance

Indivior Presents New Real-World Data at ASAM 2026 Annual Conference, Supporting Remission as a Treatment Outcome and Reinforcing the Clinical Benefits of Monthly Injectable Buprenorphine for Opioid Use Disorder